Pharmac India exhibition to be organised from 13th to 15th October 2016.
The 7th successive edition of Pharmac India exhibition organized by Indian Drug Manufacturers’ Association (GSB) is all set to host a large volume of business delegates from all parts of the world.
The Show will once again take place at the state of the art exhibition venue of Gujarat University Exhibition Hall in Ahmedabad- the Pharmaceutical Capital of India. Over the years, this industry specific exhibition has played a vital role in bringing the complete spectrum of the Pharmaceutical industry under one roof and Pharmac India always were the growth Engine the Indian Pharmaceutical industry hoped for. The show has been a perfect platform for these companies to come and exhibit their product and services offered to the ever growing Indian pharmaceutical industry as a whole. Gujarat being the Pharma hub of India is having more than 6000 SME companies in various ancillary segments of Pharma such as API’s pharmaceutical formulations, contract manufacturing, pharmaceutical machineries etc.
The Indian Pharmaceutical industry has been witnessing phenomenal growth in recent years, driven by rising consumption levels in the country and strong demand from export markets. The pharmaceutical industry in India is estimated to be worth about US$ 10 bn, growing at an annual rate of 9%. In world rankings, the domestic industry stands fourth in terms of volume and 13th in value terms. The ranking in value terms may also be a reflection of the low prices at which medicines are sold in the country.
The industry has seen tremendous progress in terms of infrastructure development, technology base and the wide range of products manufactured. Demand from the exports market has been growing rapidly due to the capability of Indian players to produce cost-effective drugs with world class manufacturing facilities. Bulk drugs of all major therapeutic groups, requiring complicated manufacturing processes are now being produced in India. Pharma companies have developed Good Manufacturing Practices (GMP) compliant facilities for the production of different dosage forms.
In addition to having GMP, WHO, several Indian companies have also been getting plant approvals from international regulatory agencies like US FDA, MCA (UK), TGA (Australia), MCC (South Africa). India possesses the highest number of US FDA approved manufacturing facilities outside the USA and currently tops in filing the drug master files (DMF) with the US FDA. This has also facilitated the domestic industry to attract contract manufacturing opportunities in the rapidly growing generics market.
The Indian pharmaceutical industry consists of manufacturers of bulk drugs and formulations. Bulk drugs include the active pharmaceutical ingredients (APIs) which are used for the manufacture of formulations. According to estimates, the proportion of formulations and bulk drugs is in the order of 75:25. There are believed to be over 60,000 formulations manufactured in India in more than 60 therapeutic segments. More than 85% of the formulations produced in the country are sold in the domestic market.
The Indian bulk drug industry has lately been gaining significant presence in the global market as foreign and multinational companies are looking to sourcing APIs and intermediates from Indian manufacturers. Factors favoring the industry are a vast resource of technical people, state-of- the-art manufacturing facilities, low cost and the advantage of the English language. As part of government’s support to increase exports, duty free zones have been set up and several manufacturers of bulk drugs have been shifting their facilities to these areas.
Globally, India ranks 3rd in terms of volume and 14th in terms of value. According to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion. Ahmedabad, Hyderabad, Mumbai, and Bangalore are the major pharmaceutical hubs of India. The domestic market is worth US$13.8 billion as of 2013, and is expected to reach US$49 billion by 2020.
Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006-07 to US$8.7 billion in 2008-09 a combined annual growth rate of 21.25%. According to PricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.
All these shows India’s surge in the Pharmaceutical segments against the world pharmaceutical industry and being the apex body in Gujarat Pharmaceutical industry, IDMA-GSB foresee a bright future for the SME sector and we whole heartedly welcome the entire pharma fraternity to this industrial networking platform which is scheduled take place from 13th to 15th October 2016 in Ahmedabad.
Pharmac India 2016- Organized jointly by IDMA- GSB and Orbit Exhibitions Pvt Ltd
